Psoriasis management
Reading File
Finding Sources
Searching PubMed
"psoriasis"[MeSH Terms] AND "treatment"[MeSH Terms]
Finding Sources
Searching PubMed
psoriasis biologics treatment guidelines
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Now I have comprehensive information from authoritative dermatology textbooks. Let me compile the full answer.
Psoriasis Management
Psoriasis is a chronic, immune-mediated inflammatory skin disease driven by the IL-23/IL-17 axis, with Th1 and Th17 T cells as central mediators. TNFα, IL-17, and IL-23 are elevated in lesional skin, and effective treatments reduce these cytokines. Histologically, lesions show epidermal acanthosis, elongated capillary loops ("squirting papillae"), and mixed lymphocytic/neutrophilic infiltrate.
Types of Psoriasis
| Type | Features |
|---|---|
| Plaque (vulgaris) | 80-90%; well-demarcated plaques with silvery scale; elbows, knees, scalp, trunk |
| Guttate | Drop-like small plaques; often follows streptococcal pharyngitis |
| Inverse | Skin folds (axilla, groin, inframammary); no classic scale; mimics tinea |
| Pustular | Localized or generalized; superficial pustules coalescing into "lakes of pus" |
| Erythrodermic | Widespread erythema + scale; life-threatening |
| Scalp | Plaques confined to scalp |
| Palmoplantar | Palms and soles |
| Nail | Pitting, onycholysis, "oil spots," onychauxis |
| Psoriatic arthritis | Joints of hands, feet, knees; can occur without skin lesions |
Critical warning: Psoriasis must NOT be treated with oral/systemic corticosteroids - this can precipitate life-threatening generalized pustular psoriasis.
Severity Assessment
The International Psoriasis Council classifies patients as candidates for:
- Topical therapy (mild disease)
- Systemic therapy (severe disease) - defined by ANY of: BSA >10%, disease at special sites (genitalia, face, palms/soles, scalp), or failure of topical therapy
Additional assessment tools: PASI (Psoriasis Area and Severity Index), DLQI (Dermatology Life Quality Index), PGA (Physician Global Assessment).
Step 1 - Topical Therapy (Mild Disease)
First-line topical agents:
- High-potency topical corticosteroids (e.g., clobetasol): 68-89% of patients achieve clear improvement (SOR: A). Most effective topical monotherapy.
- Vitamin D3 analogues - calcipotriene/calcipotriol: first-line therapy with limited toxicity. More effective than anthralin, coal tar, tazarotene.
- Fixed combination calcipotriene + betamethasone dipropionate (once daily): superior to either agent twice daily as monotherapy - the preferred initial approach.
- Tazarotene (topical retinoid): comparable efficacy to clobetasol; irritation reduced by adding a corticosteroid.
- Topical calcineurin inhibitors (tacrolimus 0.1% BID): for facial and inverse psoriasis where potent steroids are inappropriate (SOR: B).
- Roflumilast cream (PDE4 inhibitor): for major body folds.
- Coal tar / anthralin: older agents; efficacy best in inpatient/day-care settings due to staining and irritation.
Key combinations: Calcipotriene + topical corticosteroid increases efficacy and reduces side effects from both.
Step 2 - Photo(chemo)therapy (Moderate Disease)
For patients where topical therapy is inadequate or impractical:
| Modality | Notes |
|---|---|
| Narrowband UVB (NB-UVB) | Safer and more effective than broadband UVB (SOR: A); preferred phototherapy |
| Broadband UVB | Less favored |
| PUVA (psoralen + UVA) | Highest clearance rate (~70%) but rarely used now due to cumulative carcinogenicity |
Step 3 - Classic Systemic Agents (Moderate-Severe Disease)
| Drug | Dose / Notes | Key Contraindications |
|---|---|---|
| Methotrexate (MTX) | 5-15 mg/week; for widespread disease and psoriatic arthritis (SOR: A) | Excessive alcohol, active hepatitis, pregnancy |
| Cyclosporine | Highly effective (~64% clearance); NOT for long-term use | Renal insufficiency, hypertension |
| Acitretin (retinoid) | For unresponsive widespread or palmoplantar psoriasis (SOR: A); anticancer effects | Pregnancy (teratogenic) |
| Fumarates | Available in some European countries; risk of Fanconi syndrome, PML (rare) | Renal impairment |
| Hydroxyurea / 6-thioguanine | Second-line options | Myelosuppression |
| Mycophenolate mofetil | Off-label alternative | - |
Step 4 - Biologic / Targeted Immunomodulators (Moderate-Severe Disease)
Biologics are increasingly used as first-line systemic therapy for moderate-severe disease, particularly when classic systemics are contraindicated or failed. They carry no cumulative toxicity but are costly (~$60,000/year in the US).
Anti-TNF agents (1st generation)
| Agent | Route | Notes |
|---|---|---|
| Etanercept | SC | Especially valuable in psoriatic arthritis |
| Adalimumab | SC | Moderate-severe skin and PsA |
| Infliximab | IV | Rapid onset; moderate-severe skin and PsA |
| Certolizumab | SC | Safe in pregnancy (FDA/EMA approved) |
Anti-IL-12/23 (2nd generation)
| Agent | Target | Notes |
|---|---|---|
| Ustekinumab | p40 subunit of IL-12/23 | Significant improvement vs placebo; SC |
Anti-IL-17 agents (3rd generation - highest efficacy for short-term clearance)
| Agent | Target | Notes |
|---|---|---|
| Secukinumab | IL-17A | FDA + EMA approved |
| Ixekizumab | IL-17A | FDA + EMA approved |
| Brodalumab | IL-17 receptor | FDA + EMA approved |
| Bimekizumab | IL-17A + IL-17F | EMA approved (not yet FDA as of 2023) |
Anti-IL-23 agents (4th generation - best long-term drug survival)
| Agent | Target | Notes |
|---|---|---|
| Guselkumab | IL-23 (p19) | Highest drug survival at 2-6 years |
| Risankizumab | IL-23 (p19) | Highest PASI 75/90/100 rates in NMA |
| Tildrakizumab | IL-23 (p19) | FDA + EMA approved |
Special indication
- Spesolimab (anti-IL-36R): FDA + EMA approved specifically for generalized pustular psoriasis.
Comparative Efficacy (Network Meta-Analysis - PASI Rates)
| Biologic | PASI 75 | PASI 90 | PASI 100 |
|---|---|---|---|
| Risankizumab 150 mg | 89.4% | 71.7% | 41.1% |
| Ixekizumab 80 mg | 88.5% | 70.0% | 39.3% |
| Brodalumab 210 mg | 88.0% | 69.2% | 38.3% |
| Guselkumab 100 mg | 87.3% | 68.0% | 37.1% |
| Secukinumab 300 mg | 82.6% | 60.4% | 29.7% |
| Infliximab 5 mg/kg | 79.9% | 56.5% | 26.3% |
Third/fourth-generation biologics (anti-IL-17, anti-IL-23) significantly outperform 1st/2nd generation and classical systemics.
Contraindications to Biologics
Absolute: Active tuberculosis, serious active infection, allergic reaction to agent.
Class-specific:
- TNF inhibitors: avoid in NYHA III/IV heart failure, demyelinating disease, ANA+ or connective tissue disease, blood dyscrasias.
- Ustekinumab: avoid BCG vaccination within past 12 months.
- IL-17 inhibitors (secukinumab, ixekizumab, brodalumab): avoid in active Crohn disease (may exacerbate IBD).
General: Active HBV (screen all patients; treat with tenofovir/entecavir if HBsAg+), malignancy within past 5 years, pregnancy (TNF inhibitors appear safe), breastfeeding, live vaccines contraindicated while on biologics.
Combination Strategies
- Calcipotriene + topical corticosteroid: gold standard topical combination.
- MTX + adalimumab/infliximab: reduces immunogenicity (anti-drug antibody formation) with these anti-TNF agents.
- Biologic + topical: topical agents often used for persistent lesions in patients on systemic therapy.
- Avoid: Combining two systemic immunosuppressants without careful risk-benefit assessment.
Special Situations
| Situation | Preferred approach |
|---|---|
| Guttate psoriasis post-strep | Topicals + treat underlying infection |
| Erythrodermic psoriasis | Systemic therapy; avoid systemic steroids |
| Pustular psoriasis | Spesolimab (generalized); systemic agents - never systemic steroids |
| Psoriatic arthritis | TNF inhibitors (etanercept, adalimumab, infliximab), IL-17i, MTX |
| Facial/inverse | Tacrolimus, roflumilast cream; avoid potent steroids |
| Nail psoriasis | Often requires systemic therapy; nail involvement predicts PsA risk |
| Pregnancy | TNF inhibitors (especially certolizumab); avoid MTX, acitretin |
Comorbidities to Address
Psoriasis is now recognized as a systemic disease. Assess and manage:
- Psoriatic arthritis (nail involvement is a prognostic marker)
- Metabolic syndrome (obesity, dyslipidemia, hypertension)
- Cardiovascular disease (increased mortality risk)
- Depression / suicidal ideation (can justify early biologic use)
- Smoking (exacerbates disease)
- Screen for latent TB and HBV/HCV before starting biologics
Sources: Dermatology 2-Volume Set 5e (Bolonia et al.), Fitzpatrick's Dermatology in General Medicine, Textbook of Family Medicine 9e - via institutional library
This is a shared conversation. Sign in to Orris to start your own chat.